Investing Profile
David Mott
InvestorVC
Private Investor at Mott Family Capital
Montana
Your Intro Paths to David Mott
Signal uses Gmail to reveal intro paths. Email content is never read.
Sign in with Google →Networks David is a member of
Stromedix Inc. Network
267 CONNECTIONS
Stromedix Inc. Network
267 CONNECTIONS
Stromedix Inc. Network
267 CONNECTIONS
Stromedix Inc. Network
267 CONNECTIONS
Dartmouth College Network
244 CONNECTIONS
Find David Mott on
cbCurrent Investing Position
Investment Range
$100K - $10.0M
Sweet Spot
$1M
Investments On Record
21
David Mott is on these Sector & Stage Rankings
David Mott's Investments On Record (14)
| Company | StageDateRound Size | Total Raised |
|---|---|---|
Sagimet Biosciences | Series EAug 2019$7M Series BJul 2009$30M | $190M |
Cydan | Series UnknownOct 2017$34M  Series UnknownOct 2013$10M Series UnknownApr 2013$16M | $60M |
Complexa | Series CJul 2017$62M | $62M |
Nightstar Therapeutics | Series CJun 2017$45M Series BNov 2015$35M | $80M |
Vtesse | Series AJul 2016$17M | $17M |
Ardelyx | Post Ipo EquityJul 2016$110M Post Ipo EquityJun 2015$78M Series BAug 2011$30M Series AJun 2008$26M | $240M |
Clementia Pharmaceuticals | Series UnknownJun 2015$60M | $93M |
XTuit Pharmaceuticals | Series AJun 2015$22M | $22M |
David Mott's Experience
Private Investor Mott Family Capital2020 - Present
Chairman Imara, Inc2016 - Present
Chairman Epizyme2009 - Present
Chairman Ardelyx, Inc.2008 - Present
Board Member Nightstar TherapeuticsPresent
Chairman Mallinckrodt PharmaceuticalsPresent
Chairman Imara Inc.Present
Private Investor Stromedix Inc.Present
Board Member NovavaxPresent
Board Member Big Sky Youth EmpowermentPresent
Board Member Yellowstone Club Community FoundationPresent
Board Member American RiversPresent
Chairman NovavaxPresent
President & Chief Executive Officer, Vice Chairman Stromedix Inc.Present
Chief Executive Officer Stromedix Inc.Present
Chief Executive Officer and Chief Investment Officer Stromedix Inc.Present
Board Member Polyneuron Pharmaceuticals AG2019 - 2020
Board Member Tiburio Therapeutics2019 - 2020
Chairman Cydan Development, Inc.2013 - 2020
General Partner New Enterprise Associates (NEA)2008 - 2020
Chairman 3-V Biosciences2008 - 2020
Board Member NightstaRx Limited2015 - 2019
Chairman TESARO, Inc.2010 - 2019
Board Member XTuit Pharmaceuticals, Inc.2015 - 2018
Board Member Clementia Pharmaceuticals2015 - 2018
Chairman Vtesse, Inc.2015 - 2017
Board Member Edimer Pharmaceuticals2013 - 2016
Chairman Adaptimmune2014 - 2014
Chairman Prosensa2012 - 2014
Chairman Zyngenia, Inc2009 - 2014
Member Board of Trustees St. Albans School (D.C.)2008 - 2014
Chairman Mersana Therapeutics2013 - 2013
Board Member Omthera Pharmaceuticals, Inc.2011 - 2013
President & Chief Executive Officer, Vice Chairman MedImmune2000 - 2008
Board Member Shire2007 - 2008
Board Member RibX Pharmaceuticals2006 - 2008
Board Member Ambit Pharmaceuticals2004 - 2007
Member of the Board of Trustees Beauvoir Elementary School2001 - 2007
Chairman Conceptis1999 - 2003
Member of the Board of Trustees Saint James School1997 - 2003
Various Positions: President, Chief Operating Officer, Chief Financial Officer, EVP, VP, etc... MedImmune1992 - 2000
Various Positions: Vice President, Associate, Analyst Smith Barney, Harris Upham & Co.1986 - 1992
David Mott's Education
Dartmouth College Bachelor’s Degree Economics and Government
Saint James School High School
Investors who invest with David Mott
Sign in with Google →Scouts & Angels Affiliated With David Mott
Sign in with Google →